Core Insights - TC BioPharm is a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer treatment, with a specific emphasis on acute myeloid leukemia [2][3] Company Overview - TC BioPharm (Holdings) PLC is engaged in discovering, developing, and commercializing gamma-delta T cell therapies, which are immune cells that can differentiate between healthy and diseased tissue [2] - The company is recognized as a leader in the development of gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [3] Clinical Trials - TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for treating acute myeloid leukemia using its proprietary allogeneic CryoTC technology [3]

Core Viewpoint - TC BioPharm (Holdings) PLC continues trading on the Nasdaq Global Select Market under the ticker symbol 'TCBP', indicating stability in its market presence and ongoing operations [1][2]. Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer treatment, with human efficacy data specifically in acute myeloid leukemia [3]. - The company is recognized as a leader in the development of gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [4]. Clinical Trials - TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for treating acute myeloid leukemia using its proprietary allogeneic CryoTC technology, which allows for the provision of frozen products to clinics globally [4].

Core Viewpoint - TC BioPharm has received formal approval for a special stock dividend of 0.25 American Depositary Shares (ADSs) for every 1 ADS held by shareholders, with expected delivery on or about January 6, 2025 [1][5]. Group 1: Special Dividend Announcement - The special dividend of 0.25 ADSs per 1 ADS will be distributed to shareholders on the record date of January 2, 2025 [1]. - Trading of the Company's ADSs will temporarily halt at 5:00 pm on January 2, 2025, and is expected to resume around January 8, 2025, to facilitate the processing of the stock dividend [2]. Group 2: Company Overview - TC BioPharm is a clinical-stage biotechnology company specializing in gamma-delta T cell therapies for cancer treatment, being the first to conduct phase II/pivotal clinical studies in oncology [3][7]. - The company is currently conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for treating acute myeloid leukemia using proprietary CryoTC technology [3]. Group 3: Management's Perspective - The CEO of TC BioPharm, Bryan Kobel, emphasized that the special dividend is a key part of the company's capital management strategy and reflects management's confidence in the company's financial future, anticipating growth in 2025 [6].

Clinical Trial Progress - The ACHIEVE UK clinical trial is a phase II study evaluating the efficacy of TCB008 in patients with AML or MDS/AML, focusing on refractory or relapsed disease [1] - Preliminary safety data shows the 5mL dose of TCB008 is well tolerated with no drug-related Adverse Events, aligning with the safety profile [2] - 3 patients have completed the full-dose regimen in the ACHIEVE Phase 2b trial with no drug-related Adverse Events observed [5] - 10 patients have received their first dose, 9 their second dose, 4 their third dose, and 3 their fourth and final dose [9] - 9 out of 10 recruited patients are in Cohort A (relapsed/refractory), while 1 patient is in Cohort B (remission with residual disease) [9] - Recruitment for the ACHIEVE trial has been successful, with over half of Cohort A patients recruited in less than 5 months [10] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer treatment [3][11] - The company is the first to conduct phase II/pivotal clinical studies in oncology using gamma-delta T cell therapies [3] - TC BioPharm is conducting two investigator-initiated clinical trials, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using its proprietary CryoTC technology [3] Future Plans and Expectations - The company plans to recruit 14 patients initially into Cohort A and B, with an additional 10 patients per cohort after confirming study endpoints, totaling 48 patients [9] - The immediate clinical focus is on high recruitment for Cohort B in 2025 and completing data review for Cohort A [6] - The CEO highlighted the potential for an expedited review due to the patients' stage and disease expression, with minimal residual disease representing a high opportunity for TCB008 [6]

Core Viewpoint - TC BioPharm (Holdings) PLC has announced a special dividend of 0.25 American Depositary Shares (ADSs) for every 1 ADS held by shareholders, pending shareholder approval [1][2]. Group 1: Dividend Announcement - The special dividend is set to be declared on December 30, 2024, and will be payable to shareholders who own the Company's stock at the close of trading on January 2, 2025 [2]. - A general meeting of shareholders is scheduled for December 30, 2024, at The Seafield Arms Hotel in Scotland to discuss the dividend [1]. Group 2: Company Background - TC BioPharm is a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other indications, with human efficacy data in acute myeloid leukemia [6][7]. - The company is recognized as a leader in developing gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [7].

Core Viewpoint - TC BioPharm (Holdings) PLC announced a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareholder approval [1] Group 1: Dividend Announcement - The company plans to hold a general meeting of shareholders on December 30, 2024, to declare the dividend, which will be payable to shareholders owning stock at the close of trading on January 2, 2025 [2] - The CEO expressed satisfaction with the announcement, highlighting shareholder support during challenging market conditions [3] Group 2: Company Focus and Clinical Trials - TC BioPharm is a clinical-stage biopharmaceutical company specializing in gamma-delta T-cell therapies for cancer, with human efficacy data in acute myeloid leukemia [3] - The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using proprietary CryoTC technology [4] Group 3: Stock Performance - As of the last check, TCBP stock was down 1.94% to $0.46 during the premarket session [5]

Core Insights - TC BioPharm has reported positive safety data for its TCB008 treatment, allowing for exploration of higher doses in the ACHIEVE UK Trial [1][2] - The company is actively recruiting patients for both Cohort A and Cohort B in the ACHIEVE study, with plans to increase the TCB008 dose from 230 million to 819 million Gamma Delta T-Cells [2][3] - The company aims to identify the optimal biologically effective dose for patients who have exhausted other treatment options [4] Patient Recruitment and Study Progress - Over half of the Cohort A patients in Stage One of the ACHIEVE study have received TCB008, addressing an unmet clinical need for patients unable to achieve remission with existing treatments [2] - Cohort B patients, who have residual disease after initial remission, are being recruited at the current TCB008 dose of 230 million Gamma Delta T-Cells across four active clinical trial sites [3] - Two additional clinical trial sites are expected to be onboarded in the first half of 2025, increasing the total to six sites in the UK [3] Manufacturing and Operational Improvements - The company is focused on scaling up the manufacturing process to support the increased TCB008 dose, which is being developed by Dr. Lauren Bor's team [4] - Operational teams are collaborating to enhance the manufacturing process, aiming for increased yields and economic efficiencies in 2025 [5] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies for cancer treatment, with a focus on acute myeloid leukemia [6][7] - The company is recognized as a leader in developing gamma-delta T cell therapies and is conducting pivotal clinical trials using its proprietary allogeneic CryoTC technology [8]

Financial Performance - Net loss for the six months ended June 30, 2024, was £5,308,407 compared to a net income of £357,976 for the same period in 2023, indicating a significant shift in financial performance [11]. - For the six months ended June 30, 2024, the net loss was £5.3 million compared to a net income of £0.4 million for the same period in 2023 [27]. - The company reported a basic net loss per share of £0.08 for the six months ended June 30, 2024, compared to a basic net income per share of £0.12 for the same period in 2023 [11]. - The accumulated deficit increased from £38,837,290 as of December 31, 2023, to £44,145,697 as of June 30, 2024, reflecting a worsening financial position [10]. - The total shareholders' equity decreased from £2,685,230 as of December 31, 2023, to £2,004,187 as of June 30, 2024, a decline of approximately 25.4% [10]. Assets and Liabilities - Total current assets decreased from £5,700,927 as of December 31, 2023, to £3,952,319 as of June 30, 2024, representing a decline of approximately 30.6% [8]. - Total liabilities decreased from £6,246,434 as of December 31, 2023, to £4,867,208 as of June 30, 2024, a reduction of about 22.1% [10]. - Cash and cash equivalents decreased from £2,462,609 as of December 31, 2023, to £1,004,329 as of June 30, 2024, a decline of approximately 59.3% [8]. - As of June 30, 2024, cash and cash equivalents amounted to approximately £1.0 million, with working capital of £393,857 [27]. - Prepaid expenses and other current assets decreased to £1,687,869 as of June 30, 2024, from £2,194,725 as of December 31, 2023 [61]. - Accounts payable and accrued liabilities decreased to £3,211,690 as of June 30, 2024, from £4,431,840 as of December 31, 2023 [62]. Operating Expenses - Total operating expenses decreased from £7,762,970 for the six months ended June 30, 2023, to £5,496,407 for the same period in 2024, reflecting a reduction of about 29.1% [11]. - Research and development expenses for the six months ended June 30, 2024, were £2,238,234, down from £4,037,332 in the same period of 2023, a decrease of approximately 44.5% [11]. - Cash used in operating activities for the six months ended June 30, 2024, was £5.1 million, a decrease from £6.8 million in the prior year [27]. - The Company recorded operating lease expenses of £177,674 for both the six months ended June 30, 2024, and 2023 [65]. Shareholder Information - The number of weighted-average common shares outstanding increased from 3,030,825 for the six months ended June 30, 2023, to 64,905,328 for the same period in 2024, indicating a substantial increase in share issuance [11]. - The weighted average number of shares outstanding increased to 64,905,328 for the six months ended June 30, 2024, compared to 3,030,825 for the same period in 2023 [49]. - The Company issued 24,692 ordinary shares prior to the IPO, with a fair value of £3.8 million [75]. - The Company issued 23,950 ADSs representing 4,790,000 ordinary shares in a public offering, resulting in gross proceeds of $2.0 million before expenses [113]. - The Company changed its ADS ratio from one ADS representing one ordinary share to one ADS representing twenty ordinary shares on December 15, 2023 [87]. Future Outlook - The company expects to continue incurring significant losses in the foreseeable future as it develops its clinical products [26]. - The company plans to raise additional capital to address future liquidity needs, which may include equity raises or other financing options [28]. - The company has substantial doubt about its ability to continue as a going concern without adequate liquidity [29]. Capital and Financing Activities - The company raised £6.2 million ($8.0 million) in August 2024 through the issuance of ordinary shares and pre-funded warrants [27]. - The Company entered into a Securities Purchase Agreement on August 28, 2024, resulting in gross proceeds of $6.0 million from the sale of 53,558 ADSs [115]. - The Company received approximately £3.1 million from the exercise of Existing Warrants by holders in May 2024 [85]. - The Company has received approximately $1.1 million in cash receipts from the exercise of warrants as of November 21, 2024 [27]. - The Company recognized an incremental fair value of £248,659 for modified share options granted to five grantees in March 2024 [98]. Compensation and Management - TC Biopharm (Holdings) PLC granted a one-time bonus of $125,000 to CEO Bryan Kobel and CFO Martin Thorp [117]. - Compensation for Chairwoman Arlene Morris increased to $75,000 per year, effective Q3 2024 [117]. - Compensation for Chairman of the Audit Committee James Culverwell increased to $65,000 per year, effective Q3 2024 [117].

Core Insights - TC BioPharm has made significant progress in 2024, enhancing its position as a leading clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer and other indications [2][5] Operational Achievements - The ACHIEVE UK trial has advanced rapidly, with 8 patients dosed, including 2 who have received their final dose, all in Cohort A [2] - A new site has opened at Guy's and St. Thomas Hospital, a leading oncology clinic in the UK, with plans to open two more sites in Q1 2025 [2] - The compassionate use program for TCB008 has garnered interest from physicians in the UK and US, indicating its potential broad application in various cancer types [2] Financial Performance - In Q1 2024, the company reduced cash burn by 50%, aligning R&D efforts towards commercial applications [2] - Approximately $8 million in capital was added to the balance sheet in August through a non-brokered transaction with an investor group [2] Strategic Initiatives - TC BioPharm has signed two non-binding Letters of Intent (LOIs) for acquisitions in cell therapy modalities beyond TCB008 [2] - The company plans to initiate proof of concept for preclinical trials for Mpox treatment with a leading infectious disease expert in the UK [2] - A strategic partnership has been formed with a leading university for an AI initiative in donor screening for allogeneic cell therapies, a potentially multi-billion dollar market [2] Future Objectives - The company aims to continue executing its strategic initiatives and operational plans for 2025, including advancing Cohort B to a data readout and amending the Phase 1b FDA trial timeline [3] - TC BioPharm expects to compile clinical data for Cohort A in H1 2025 [3]

Core Viewpoint - TC BioPharm confirms its compliance with all Nasdaq listing requirements and refutes rumors of potential delisting from the exchange [1][2] Company Compliance and Response - The company has stated that it is not in danger of being delisted from Nasdaq and remains compliant with all listing requirements [1][2] - TC BioPharm plans to take action against false claims that aim to create negative market dynamics [2] Company Overview - TC BioPharm is a clinical-stage biotechnology company focused on developing gamma-delta T cell therapies for cancer treatment, with human efficacy data in acute myeloid leukemia [4] - The company is a leader in this field and has conducted phase II/pivotal clinical studies in oncology [4] - TC BioPharm is currently conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using proprietary CryoTC technology [4]